WINTON GROUP Ltd reduced its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) by 66.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,732 shares of the biotechnology company’s stock after selling 54,473 shares during the period. WINTON GROUP Ltd’s holdings in ImmunoGen were worth $125,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of IMGN. Nisa Investment Advisors LLC grew its stake in ImmunoGen by 116.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,390 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 5,600 shares during the period. Stonegate Investment Group LLC purchased a new stake in ImmunoGen in the 2nd quarter worth approximately $55,000. XTX Topco Ltd purchased a new stake in ImmunoGen in the 1st quarter worth approximately $62,000. Northwestern Mutual Wealth Management Co. grew its stake in ImmunoGen by 544.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 16,750 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 14,150 shares during the period. Finally, TFC Financial Management grew its stake in ImmunoGen by 18.1% in the 1st quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 2,750 shares during the period. 95.58% of the stock is owned by hedge funds and other institutional investors.
ImmunoGen Trading Up 1.9 %
Shares of ImmunoGen stock opened at $5.32 on Tuesday. The company has a fifty day moving average price of $5.47 and a 200 day moving average price of $4.97. ImmunoGen, Inc. has a twelve month low of $3.10 and a twelve month high of $7.77. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -6.49 and a beta of 1.06.
Analysts Set New Price Targets
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.